Failure to respond to interferon-α 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C Authors
Received: 22 July 1997 Revised: 30 November 1997 Accepted: 15 December 1997 DOI:
Cite this article as: Kageyama, F., Kobayashi, Y., Murohisa, G. et al. Biol Trace Elem Res (1998) 64: 185. doi:10.1007/BF02783335 ABSTRACT
Recent reports suggest the hepatic iron concentration (HIC) may influence the activity of hepatitis and the response to interferon (IFN) therapy in patients with chronic hepatitis C (CH-C). We have evaluated iron status in 28 patients with CH-C and determined if pretreatment iron status can predict the response to IFN-α therapy in these patients. Increased serum iron, transferrin saturation, and ferritin levels were observed in 3 (11%), 11 (39%), and 5 (18%) patients, respectively. Hepatic iron deposits were histologically detected in 17 (61%) patients, and 14 of them had stainable hepatocytic iron. However, all HIC values were within the normal range (203–1279 μg/g). Seven of 17 patients treated with IFN-α for 6 mo had normalization of serum transaminases and disappearance of serum HCV-RNA (responders). Nonresponders had a significantly higher median HIC compared with responders (710 vs 343 μg/g, respectively;
p < 0.05). There was no significant difference in other pretreatment iron parameters, serum HCV-RNA level, or HCV-genotype between responders and nonresponders. In conclusion, mild hepatic iron accumulation occurs in patients with CH-C. Increased hepatic iron stores are associated with poor response to IFN therapy. Pretreatment HIC may be an additional host-specific parameter with a predictive value for responsiveness to IFN therapy, in addition to well-known predictive viral factors. Index entries Iron chronic hepatitis C liver interferon-α therapy References
H. L. Bonkovsky, B. F. Banner, R. W. Lambrecht, and R. B. Rubin, Iron in liver diseases other than hemochromatosis,
Semin Liv Dis
, 65–82 (1996).
A. Piperno, R. D’Alba, S. Fargion, L. Roffi, M. Sanpietro, S. Parma, et al., Liver iron concentration in chronic viral hepatitis: a study of 98 patients,
Eur. J. Gastroenterol. Hepatol.
, 1203–1208 (1995).
B. R. Bacon, M. W. Fried, and A. M. Di Bisceglie, A 39-year-old man with chronic viral hepatitis, elevated serum ferritin values, and a family history of hemochromatosis,
Semin. Liv. Dis.
13, 101–105 (1993).
C. Q. Edwards, L. M. Griffen, D. Goldgar, C. Drummond, M. H. Skolnick, and J. P. Kushner, Prevalence of hemochromatosis among 11,065 presumably healthy blood donors,
N. Engl. J. Med.
, 1355–1362 (1988).
C. Q. Edward, L. M. Griffen, and J. P. Kushner, Disorders of excess iron,
26 ( Suppl
3), 30–36 (1991).
M. Shindo, A. M. Di Bisceglie, and J. H. Hoofnagle, Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon,
, 1013–1016 (1992).
L. Chemello, P. Bonetti, L. Cavalletto, F. Talato, V. Donadon, P. Casarin, et al., Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C,
, 700–706 (1995).
M. Martinot-Peignoux, P. Marcellin, M. Pouteau, C. Casternau, N. Boyer, M. Poliquin, et al., Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C,
, 1050–1056 (1995).
D. H. Van Thiel, L. Friedlander, S. Fagiuoli, H. I. Wright, W. Irish, J. S. Gavaler, et al., Response to α-interferon therapy is influenced by the iron content of the liver,
, 410–115 (1994).
J. K. Olynyk, K. R. Reddy, A. M. Di Bisceglie, L. J. Feffers, T. I. Parker, J. L. Radick, et al., Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C,
, 1104–1109 (1995).
N. Izumi, N. Enomoto, M. Uchihara, T. Murakami, K. Ono, O. Noguchi, et al., Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus,
Dig. Dis. Sci.
, 989–94 (1996).
B. F. Banner, A. L. Barton, E. E Cable, L. Smith, and H. L. Bonkovsky, A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C,
8, 232–238 (1995).
A. L. Barton, E Barbara, B. E Banner, E. E Cable, and H. L. Bonkovsky, Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy,
Am. J. Clin. Pathol.
, 419–424 (1995).
Y. Ikura, H. Morimoto, H. Johmura, M. Fukui, and M. Sakurai, Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C,
Am. J. Gastroenterol.
, 1367–1373 (1996).
J. Torrance and T. H. Bothwell, A simple technique for measuring storage iron concentrations in formalinized liver samples,
S. Afr. J. Med. Sci.
, 9–11 (1968).
K. M. Summers, J. W. Halliday, and L. W. Powell, Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index,
, 20–5 (1990).
V. J. Desmet, M. Gerber, J. H. Hoofnagle, M. Manns, and P. J. Sheuer, Classification of chronic hepatitis C: diagnosis, grading and staging,
, 1513–1520 (1994).
H. Okamoto, S. Okada, Y. Sugiyama, T. Tanaka, Y. Sugai, Y. Akahane, et al., Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region,
Jpn. J. Exp. Med.
, 215–222 (1990).
H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, et al, Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infection source,
J. Gen. Virol.
, 673–679 (1992).
A. M. Di Bisceglie, C. A. Axiotis, J. H. Hoofnagle, and B. R. Bacon, Measurement of iron status in patients with chronic hepatitis,
, 2108–2113 (1992).
T. Isomura, M. Yano, H. Hayashi, and N. Sakamoto, Excess iron in the liver of patients with chronic hepatitis C,
J. Clin. Electron. Microsc.
25, 231–237 (1992).
M. Kobune, Y. Kohga, J. Kato, E. Miyazaki, and Y. Niitsu, Interleukin-6 enhances hepatic transferrin uptake and ferritin expression in rats,
, 1468–1475 (1994).
J. N. Feder, A. Gnirke, W. Thomas, J. N. Feder, A. Gnirke, W. Thomas, et al., A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis,
, 399–408 (1996).
R. S. Britton, Metal-induced hepatotoxicity,
Semin. Liv. Dis.
16, 3–11 (1996).
H. Hayashi, T. Takukawa, N. Nishimura, M. Yano, T. Isomura, and N. Sakamoto, Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron,
Am. J. Gastroenterol.
, 986–988 (1994).
F. Farinati, R. Cardin, N. De Maria, G. D. Libera, C. Martin, E. Lecis, et al., Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis,
, 449–456 (1995).
N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, et al., Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection,
N. Engl. J. Med.
, 77–81 (1996).
N. Enomoto, I. Sakuma, Y Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, et al., Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus lb,
J. Clin. Invest.
, 224–230 (1995).